These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 20156689

  • 21. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.
    Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ.
    Leukemia; 2009 Mar; 23(3):590-4. PubMed ID: 18784745
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
    Kiyoi H.
    Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib.
    Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL.
    Biomol NMR Assign; 2011 Oct; 5(2):221-4. PubMed ID: 21523440
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
    Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1543-7. PubMed ID: 20137931
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.
    Haematologica; 2008 May 01; 93(5):653-61. PubMed ID: 18367480
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.